PT - JOURNAL ARTICLE AU - Mostovov, Andrey AU - Jacobs, Damien AU - Farid, Leila AU - Dhellin, Paul AU - Baille, Guillaume TI - Excellent reliability of the six-minute walking distance measured by FeetMe<sup>®</sup> insoles at home AID - 10.1101/2023.04.28.23289259 DP - 2023 Jan 01 TA - medRxiv PG - 2023.04.28.23289259 4099 - http://medrxiv.org/content/early/2023/05/02/2023.04.28.23289259.short 4100 - http://medrxiv.org/content/early/2023/05/02/2023.04.28.23289259.full AB - Background Wearable technology provides an opportunity for new ways of monitoring patient gait remotely, through at-home self-administered six-minute walk tests (6MWTs). The purpose of this study was to evaluate the reliability and repeatability of FeetMe® insoles, a wearable gait assessment device, for measuring the six-minute walking distance (6MWD) during tests conducted independently at home by healthy volunteers.Methods Participants (n=21) performed two 6MWTs at home while wearing the FeetMe® insoles, and two 6MWTs at hospital while wearing FeetMe® insoles and being assessed by a rater. All assessments were performed with a one-week interval between tests, no assistance was provided to the participants at home.Results and conclusion The agreement between the 6MWD measurements made at baseline and at Week 1 was good for all test configurations and was highest for the at-home FeetMe® measurements, with an intraclass correlation coefficient (ICC) of 0.95, standard error of the measurement (SEM) of 15.02 m and coefficient of variation (CV) of 3.33%, compared to ICCs of 0.79 and 0.78, SEMs of 25.65 and 26.65 and CVs of 6.24% and 6.10% for the rater and FeetMe® measurements at hospital, respectively. Our work demonstrates that the FeetMe® system could provide a reliable solution allowing individuals to self-administer 6MWTs independently at home.Author Summary At-home patients monitoring using wearable tools presents numerous advantages for regular care and clinical studies. Patients benefit from the convenience of not having to travel to a clinic for assessments, which is particularly helpful for those in remote areas or with mobility issues. Besides, at-home monitoring allows for more frequent assessments, leading to more accurate clinical decision-making and timely intervention, which ultimately results in enhanced patient care. For the same reasons, it can improve patients recruitment and retention in clinical studies.The six-minute walk test (6MWT) is a commonly used standardized assessment of functional capacity in patients with various diseases. We evaluated the reliability and repeatability of FeetMe® insoles, a wearable gait assessment device, for measuring the six-minute walking distance (6MWD) at home. Our analysis of the data from 21 healthy volunteers showed that the FeetMe® insoles were as reliable at home as they were in the standard clinical setting and as a conventional way of assessing the 6MWD. In addition, the insoles provided extensive gait analysis, which may allow for more precise conclusions regarding the patient’s state and its evolution than the 6MWD alone. We conclude that the FeetMe® device is an excellent tool for at-home patients monitoring.Competing Interest StatementThe FeetMe® company was a partner in this study: A.M. is employee of the FeetMe® company, D.J. and L.F. were employees of the company at the time of the study and P.D. was the company's intern at the time of the study. The FeetMe® company provided significant financial support for this study. G.B. has no conflicts of interest to disclose and has no link of interest to the FeetMe® company.Clinical TrialID RCB 2021-A00037-34Funding StatementThis research received no external funding. The FeetMe® company provided significant financial support for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in accordance with the Declaration of Helsinki and approved by the Comité de Protection des Personnes Est I (ID RCB 2021-A00037-34) on June 10th, 2021I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData available on request due to restrictions e.g. privacy or ethical.